John A Fort

John A Fort, M.D.

Clinical Associate Professor

Department: MD-PEDS-HEMATOLOGY
Business Phone: (352) 273-9120
Business Email: john.fort@ufl.edu

About John A Fort

John Fort, M.D., attended the University of Louisville for medical school and his pediatric residency. He then completed his fellowship in pediatric hematology/oncology at the University of Florida. Dr. Fort served as an assistant professor at George Washington University and an attending physician at Miami Children’s Hospital before joining the University of Florida faculty in 2012. He is a member of the American Society of Bone Marrow Transplantation, American Society of Pediatric Hematology/Oncology, Children’s Oncology Group, Pediatric Blood and Marrow Transplant Consortium and National Marrow Donor Program.

Teaching Profile

Courses Taught
2018
MDC7400 Pediatric Clerkship
2018
MDC7401 Senior Pediatric Clk
2018
MDT7400 Elect Top/Pediatrics

Board Certifications

  • Pediatric Hematology/Oncology
    American Board of Pediatrics

Clinical Profile

Specialties
  • Pediatrics
Subspecialties
  • Pediatric Hematology-Oncology
Areas of Interest
  • Bone marrow transplant
  • Brain tumor – children

Publications

2021
Pediatric HCT in Florida (2014 -2016): A report from the FPBCC.
Pediatric transplantation. 25(5) [DOI] 10.1111/petr.13931. [PMID] 33245834.
2021
Race as a factor in donor selection and survival of children with hematologic malignancies undergoing hematopoietic stem cell transplant in Florida.
Pediatric blood & cancer. 68(10) [DOI] 10.1002/pbc.29180. [PMID] 34121322.
2020
Infusion of Hematopoietic Stem Cell Products Using Pump Mechanism: An Approach Worth Consideration?
Journal of pediatric hematology/oncology. 42(3):e174-e176 [DOI] 10.1097/MPH.0000000000001491. [PMID] 31033784.
2020
Primary pulmonary artery sarcoma in the pediatric patient: Review of literature and a case report.
Radiology case reports. 15(7):1110-1114 [DOI] 10.1016/j.radcr.2020.05.016. [PMID] 32477441.
2018
Late Effects After Radiotherapy for Childhood Low-grade Glioma.
American journal of clinical oncology. 41(3):307-312 [DOI] 10.1097/COC.0000000000000267. [PMID] 26808258.
2017
A Case Presentation: Rare Occurrence of an Adolescent Male Presenting With an ATRT and Simultaneous Low-grade Glioneuronal Tumor.
Journal of pediatric hematology/oncology. 39(8):e456-e459 [DOI] 10.1097/MPH.0000000000000871. [PMID] 28731919.
2016
FGFR1 N546K and H3F3A K27M mutations in a diffuse leptomeningeal tumour with glial and neuronal markers.
Histopathology. 69(4):704-7 [DOI] 10.1111/his.12983. [PMID] 27061725.
2015
Optic nerve pilomyxoid astrocytoma in a patient with Noonan syndrome.
Pediatric blood & cancer. 62(6):1084-6 [DOI] 10.1002/pbc.25382. [PMID] 25585602.
2014
Late toxicity following craniospinal radiation for early-stage medulloblastoma.
Acta oncologica (Stockholm, Sweden). 53(4):471-80 [DOI] 10.3109/0284186X.2013.862596. [PMID] 24564687.
2014
Local control in non-metastatic medulloblastoma.
Acta oncologica (Stockholm, Sweden). 53(9):1151-7 [DOI] 10.3109/0284186X.2014.932434. [PMID] 24991891.
2014
Pa32540 (a Coordinated-Delivery Tablet of Enteric-Coated Aspirin 325 Mg and Immediate-Release Omeprazole 40 Mg) Versus Enteric-Coated Aspirin 325 Mg Alone in Subjects At Risk for Aspirin-Associated Gastric Ulcers: Results of Two 6-Month, Phase 3 Studies
American heart journal. 168(4):495+-502.e4 [DOI] 10.1016/j.ahj.2014.05.017. [PMID] 25262259.
2013
Factors Impacting Long-Term Local Control in Nonmetastatic Medulloblastoma
International Journal of Radiation Oncology Biology Physics. 87
2013
Late Effects Following Radiation Therapy for Childhood Low-Grade Glioma
International Journal of Radiation Oncology Biology Physics. 87
2011
Modified Severity of Dyspepsia Assessment pain scale: a new tool for measuring upper abdominal pain in osteoarthritis patients taking NSAIDs.
Patient related outcome measures. 2:135-43 [DOI] 10.2147/PROM.S18077. [PMID] 22915974.
1990
CD9 is an unreliable antibody for bone marrow purging.
Progress in clinical and biological research. 333:185-9 [PMID] 2408060.
1989
Adult-type T-cell lymphoma in an adolescent with human T-lymphotropic virus type 1 seropositivity.
Medical and pediatric oncology. 17(3):236-8 [PMID] 2747594.
1989
Thrombocytosis and hyperkalemia revisited.
The American journal of pediatric hematology/oncology. 11(3):334-6 [PMID] 2782564.
1988
High-risk Ewing’s sarcoma: end-intensification using autologous bone marrow transplantation.
International journal of radiation oncology, biology, physics. 15(1):53-9 [PMID] 3292490.
1988
Vasoocclusion with homozygous hemoglobin-C disease.
The American journal of pediatric hematology/oncology. 10(4):323-5 [PMID] 3239710.

Grants

Jan 2022 ACTIVE
CTOA
Role: Principal Investigator
Funding: UNIV OF FLORIDA
Jul 2021 – Feb 2022
A Phase 1 Pilot Study to Evaluate the Safety and Feasibility of Gene Therapy with CSL200 (Autologous Enriched CD34+ Cell Fraction that Contains CD34+ Cells Transduced with Lentiviral Vector Encoding Human ?-GlobinG16D and Short-Hairpin RNA734) in Adult Subjects with Severe Sickle Cell Disease
Role: Principal Investigator
Funding: DRUGDEV INC via CSL BEHRING
Aug 2019 ACTIVE
A phase 2, Multicenter, Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab, with or without Hydroxyurea/Hydroxycarbamide, in Sequential, Descending Age Groups of Pediatric Sickle Cell Disease Patients with Vaso-Occlusive Crisis
Role: Principal Investigator
Funding: NOVARTIS PHARMACEUTICALS CORP
Jul 2019 ACTIVE
FLDOH CMS Hematology/Oncology – COQXE A4
Role: Project Manager
Funding: FL DEPT OF HLTH CHILDRENS MED SERVS via US DEPT OF HLTH & HUMAN SER OFFICE OF RE
Jun 2019 ACTIVE
A Phase 3 Study of Eltrombopag vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children
Role: Principal Investigator
Funding: CHILDRENS HOSPITAL CORPORATION via NOVARTIS PHARMACEUTICALS CORP
Sep 2017 – Feb 2022
Multicenter, Open Label, Phase 3 Trial of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study)
Role: Principal Investigator
Funding: PRA HEALTH SCIENCES via ATARA BIOTHERAPEUTICS INC
Aug 2017 – Aug 2022
Safety Follow-up Through 180 Days of Treatment with Remestemcel-L in Study MSB-GVHD001 in Pediatric Patients who have Failed to Respond to Steroid Treatment for Acute GVHD
Role: Principal Investigator
Funding: IQVIA via MESOBLAST INTERNATIONAL SARL
Jul 2017 ACTIVE
Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease
Role: Principal Investigator
Funding: NATL MARROW DONOR PROGRAM via NATL INST OF HLTH NHLBI
Jul 2017 – Jul 2022
Multi-center Expanded Access Protocol of Allogenic Epstein-Barr Virus Cytotoxic T Lymphocytes (EBV-CTLs) for Patients with EBV- Associated Lymphomas and Lymphoproliferative Disorders in Immunocompromised Patients for Whom there are No other Comparable Options Multicenter Expanded Access Protocol of ATA129 for Subjects with Epstein-Barr Virus-Associated Viremia or Malignancies for Whom there are No Appropriate Alternative Therapies
Role: Principal Investigator
Funding: PRA HEALTH SCIENCES via ATARA BIOTHERAPEUTICS INC
Feb 2017 – Feb 2022
A Single-arm, Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
Role: Principal Investigator
Funding: IQVIA via MESOBLAST INTERNATIONAL SARL

Education

Fellowship – Pediatric Hematology/Oncology
1989 · University of Florida
Residency – Pediatrics
1986 · University of Louisville
Internship – Pediatrics
1984 · University of Louisville
Medical Degree
1983 · University of Louisville

Contact Details

Phones:
Business:
(352) 273-9120
Emails:
Business:
john.fort@ufl.edu
Addresses:
Business Mailing:
PO BOX 100298
GAINESVILLE FL 326100001
Business Street:
HD-209 B
1600 SW Archer Road
GAINESVILLE FL 32610